Preskoči na sadržaj
Digitalni repozitorijum Stomatološkog fakulteta u Pančevu

Pun zapis

dc:titleDopaminergic receptors on CD4+ T naïve and memory lymphocytes correlate with motor impairment in patients with Parkinson’s disease.
dc:creatorN., Kustrimovic
dc:creatorE., Rasini
dc:creatorM., Legnarao
dc:creatorR., Bombelli
dc:creatorI., Aleksic
dc:creatorF., Blandini
dc:creatorC., Comi
dc:creatorM., Mauri
dc:creatorB., Minafra
dc:creatorV., Sanchez-Guajardo
dc:creatorF., Marino
dc:creatorM., Cosentino
dc:subjectParkinson's disease
dc:subjectdopamine receptors
dc:subjectCD4+ T cells
dc:subjectnaive T cells
dc:subjectmemory T cells
dc:subjectalpha-synuclein
dc:subjectmotor impairment
dc:subjectneuroinflammation
dc:subjectD1-like receptors
dc:subjectD2-like receptors
dc:subjectimmunotherapy
dc:subjectdopamine
dc:descriptionAbstract Parkinson’s disease (PD) is characterized by loss of dopaminergic neurons in substantia nigra pars compacta, α-synuclein (α-syn)-rich intraneuronal inclusions (Lewy bodies), and microglial activation. Emerging evidence suggests that CD4+ T lymphocytes contribute to neuroinflammation in PD. Since the mainstay of PD treatment is dopaminergic substitution therapy and dopamine is an established transmitter connecting nervous and immune systems, we examined CD4+ T naive and memory lymphocytes in PD patients and in healthy subjects (HS), with specific regard to dopaminergic receptor (DR) expression. In addition, the in vitro effects of α-syn were assessed on CD4+ T naive and memory cells. Results showed extensive association between DR expression in T lymphocytes and motor dysfunction, as assessed by UPDRS Part III score. In total and CD4+ T naive cells expression of D1-like DR decrease, while in T memory cells D2-like DR increase with increasing score. In vitro, α-syn increased CD4+ T memory cells, possibly to a different extent in PD patients and in HS, and affected DR expression with cell subset-specific patterns. The present results support the involvement of peripheral adaptive immunity in PD, and may contribute to develop novel immunotherapies for PD, as well as to better use of current dopaminergic antiparkinson drugs.
dc:publisherNature Portfolio
dc:date2016
dc:typeinfo:eu-repo/semantics/article
dc:typeinfo:eu-repo/semantics/publishedVersion
dc:identifierhttps://stomatoloskifakultet.rs/nauka/publikacija/521
dc:identifierDOI 10.1038/srep33738
dc:identifierISSN 2045-2322
dc:sourceScientific Reports 33738(6): 33738
dc:languageen
dc:rightsinfo:eu-repo/semantics/closedAccess
dc:rightsSva prava zadržana